New strategies in controlling drug resistance

Journal of Managed Care Pharmacy

Volumn 13, Issue 8 SUPPL. A, 2007, Pages

  Frame, David ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Dasatinib; Drug cost; Drug resistance; Imatinib; Leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CETUXIMAB; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; MUTANT PROTEIN; NILOTINIB; PEGINTERFERON; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG WITHDRAWAL; ECONOMIC EVALUATION; GENE AMPLIFICATION; HEALTH CARE COST; HEMODIALYSIS; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MANAGED CARE; MONOTHERAPY; MORTALITY; NEUTROPENIA; PATIENT COMPLIANCE; PLASMA PROTEIN BINDING; PLEURA EFFUSION; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 36248955149     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s8-a.13     Document Type: Review

References (26)

1. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha-1-acid glyco-protein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003;9:625-32.
2. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739-45.
3. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-80.
4. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005;23:6316-24.
5. Picard S, Titier K, Etienne G, et al. Trough plasma imatinib concentrations are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 2141.
6. Larson RA, Druker BJ, Guilhot F, et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 429.
7. Deininger MWN. Management of early stage disease. Hematology. 2005;2005:174-82.
8. Cortes J, Giles F, Salvado AJ, et al. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT trial study group. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 2149.
9. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61.
10. Besa EC, Woermann U. Chronic myelogenous leukemia, eMedicine. Available at: http://www.emedicine.com/med/topic371.htm. Accessed August 14, 2007.
11. Rosti G, Castagnetti F, Amabile M, et al. Imatinib high dose (800 mg): results of a phase II trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Deli'Adulto) CML working party in intermediate sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high sokal risk patients. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 4776.
12. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-75.
13. Talpaz M, Shah NP, Kantarjian H, et al. Dasatmib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-41.
14. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-37
15. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-39.
16. Baccarani M, Kantarjian HM, Apperley JF, et al. Efficacy of dasatinib (SPRYCEL®) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 'START-C' phase II study. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 164.
17. Shah N, Pasquini R, Rousselot P, et al. Dasatinib (SPRYCEL®) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib: results of the CA180-017 START-R randomized study. Blood (ASH Annual Meeting Abstracts). 2006;108: Abstract 167.
18. Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;109:1556-60.
19. Hochhaus A, Kim DW, Rousselot P, et al. Dasatinib (SPRYCEL®) 50 mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to imatinib: results of the CA180-034 study. Blood (ASH Annual Meeting Abstracts). 206;108:Abstract 166.
20. Hehlmann R, Pfirrmann M, Hochhaus A, et al. Randomized comparison of primary allogeneic stem cell transplantation and best available drug treatment in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 427.
21. Mahon F-X, Huguet F, Etienne G, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission: an update follow up. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 2154.
22. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12:570-77. Available at: www.amcp.org/data/jmcp/ contemporary_subjects_570_577.pdf.
23. Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther. 2004;26:1924-33.
24. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. 2005;23:515-26.
25. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101:2574-83.
26. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005;25:325-34.